Xarelto for VTE Prophylaxis After Hip or Knee Arthroplasty

Xarelto in the Prophylaxis of Post Surgical Venous Thromboembolism After Elective Major Orthopedic Surgery of Hip or Knee

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00831714

Acronym

XAMOS

Enrollment

19076

Registered

2009-01-29

Start date

2009-02-28

Completion date

2013-04-30

Last updated

2017-01-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Venous Thromboembolism

Keywords

Prophylaxis of Venous Thromboembolism

Brief summary

The main goal is to provide additional information to the risk-benefit assessment of the drug.

Interventions

DRUGRivaroxaban (Xarelto, BAY59-7939)

Female and male patients, who are at least 18 years of age and will undergo elective hip or knee arthroplasty, after the decision for VTE prophylaxis with Rivaroxaban has been made

DRUGStandard care treatment for VTE prophylaxis

Female and male patients, who are at least 18 years of age and will undergo elective hip or knee arthroplasty, after the decision for a pharmacologic VTE prophylaxis treatment other than rivaroxaban has been made

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Female and male patients who will undergo elective hip or knee arthroplasty.

Exclusion criteria

Design outcomes

Primary

Measure	Time frame
Data collection on: Bleeding events reported as serious or non-serious adverse events; Symptomatic thromboembolic events (DVT, PE) reported as adverse events; Uncommon adverse events (incidence rate between 0.1 % and 1 %); All cause mortality	During observation period of three months

Countries

Australia, Austria, Belgium, Bosnia and Herzegovina, Brazil, Canada, Chile, China, Colombia, Cyprus, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hong Kong, Hungary, India, Italy, Latvia, Lebanon, Lithuania, Mexico, Netherlands, North Macedonia, Norway, Philippines, Portugal, Serbia, Singapore, Slovakia, South Africa, South Korea, Spain, Sweden, Switzerland, United Arab Emirates, United Kingdom, Venezuela, Vietnam

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026